Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes
JAMA · 18.07.2023 · 330 (3) · 228
DOI: 10.1001/jama.2023.11313 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 18.07.2023. Verfasst von Ildiko Lingvay und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Internal Medicine and Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin, Long-Acting. Die Arbeit wurde bisher 144-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Importance Once-weekly insulin icodec could provide a simpler dosing alternative to daily basal insulin in people with type 2 diabetes.
Objective
To evaluate the efficacy and safety of once-weekly icodec vs once-daily insulin degludec in people with insulin-naive type 2 diabetes. Design, Setting, and Participants Randomized, double-masked, noninferiority, treat-to-target, phase 3a trial conducted from March 2021 to June 2022 at 92 sites in 11 countries in adults with type 2 diabetes treated with any noninsulin glucose-lowering agents with hemoglobin A 1c (HbA 1c ) of 7%-11% (53-97 mmol/mol).
Interventions
Participants were randomly assigned in a 1:1 ratio to receive either once-weekly icodec and once-daily placebo (icodec group; n = 294) or once-daily degludec and once-weekly placebo (degludec group; n = 294). Main Outcomes and Measures The primary end point was change in HbA 1c from baseline to week 26 (noninferiority margin, 0.3% percentage points). Secondary end points included change in fasting plasma glucose from baseline to week 26, mean weekly insulin dose during the last 2 weeks of treatment, body weight change from baseline to week 26, and number of level 2 (clinically significant; glucose level <54 mg/dL) and level 3 (severe; requiring external assistance for recovery) hypoglycemic episodes.
Results
Among 588 randomized participants (mean [SD] age, 58 [10] years; 219 [37%] women), 564 (96%) completed the trial. Mean HbA 1c level decreased from 8.6% (observed) to 7.0% (estimated) at 26 weeks in the icodec group and from 8.5% (observed) to 7.2% (estimated) in the degludec group (estimated treatment difference [ETD], −0.2 [95% CI, −0.3 to −0.1] percentage points), confirming noninferiority ( P < .001) and superiority ( P = .002). There were no significant differences between the icodec and degludec groups for fasting plasma glucose change from baseline to week 26 (ETD, 0 [95% CI, −6 to 5] mg/dL; P = .90), mean weekly insulin dose during the last 2 weeks of treatment, or body weight change from baseline to week 26 (2.8 kg vs 2.3 kg; ETD, 0.46 [95% CI, −0.19 to 1.10] kg; P = .17). Combined level 2 or 3 hypoglycemia rates were numerically higher in the icodec group than the degludec group from week 0 to 31 (0.31 vs 0.15 events per patient-year exposure; P = .11) and statistically higher in the icodec group from week 0 to 26 (0.35 vs 0.12 events per patient-year exposure; P = .01). Conclusions and Relevance Among people with insulin-naive type 2 diabetes, once-weekly icodec demonstrated superior HbA 1c reduction to once-daily degludec after 26 weeks of treatment, with no difference in weight change and a higher rate of combined level 2 or 3 hypoglycemic events in the context of less than 1 event per patient-year exposure in both groups. Trial Registration ClinicalTrials.gov Identifier: NCT04795531
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Department of Internal Medicine and Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas.
- Novo Nordisk A/S, Søborg, Denmark.
- University of Nebraska Medical Center, Omaha, Nebraska.
- CHU de Toulouse & UMR1297/I2MC, Inserm, Université Toulouse 3, Toulouse, France.
- Novo Nordisk Service Centre India Private Ltd, Bangalore, India.
- Curitiba Diabetes Centre, Department of Endocrine Diseases, Hospital Nossa Senhora das Graças, Curitiba, Brazil.
Zitieren
APA
Lingvay, I., Asong, M., Desouza, C., Gourdy, P., Kar, S., Vianna, A., Vilsbøll, T., Vinther, S., & Mu, Y. (2023). Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes. JAMA, 330(3), 228. https://doi.org/10.1001/jama.2023.11313
Vancouver
Lingvay I, Asong M, Desouza C, Gourdy P, Kar S, Vianna A, et al. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes. JAMA. 2023;330(3):228. doi:10.1001/jama.2023.11313
BibTeX
@article{Lingvay2023,
author = {Lingvay, Ildiko and Asong, Marisse and Desouza, Cyrus and Gourdy, Pierre and Kar, Soumitra and Vianna, André and Vilsbøll, Tina and Vinther, Siri and Mu, Yiming},
title = {Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes},
journal = {JAMA},
year = {2023},
volume = {330},
number = {3},
pages = {228},
doi = {10.1001/jama.2023.11313}
}
EUVIMED